Lixin Rui
aDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 53792, USA
bCarbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, 53792, USA
More InformationCorresponding author: E-mail address: lrui@medicine.wisc.edu (Lixin Rui)
Publish Date:2020-07-25
Abstract
Abstract
DNA methyltransferases (DNMTs) are an evolutionarily conserved family of DNA methylases, transferring a methyl group onto the fifth carbon of a cytosine residue. The mammalian DNMT family includes three major members that have functional methylation activities, termed DNMT1, DNMT3A, and DNMT3B. DNMT3A and DNMT3B are responsible for methylation establishment, whereas DNMT1 maintains methylation during DNA replication. Accumulating evidence demonstrates that regulation of DNA methylation by DNMTs is critical for normal hematopoiesis. Aberrant DNA methylation due to DNMT dysregulation and mutations is known as an important molecular event of hematological malignancies, such as DNMT3A mutations in acute myeloid leukemia. In this review, we first describe the basic methylation mechanisms of DNMTs and their functions in lymphocyte maturation and differentiation. We then discuss the current understanding of DNA methylation heterogeneity in leukemia and lymphoma to highlight the importance of studying DNA methylation targets. We also discuss DNMT mutations and pathogenic roles in human leukemia and lymphoma. We summarize the recent understanding of how DNMTs interact with transcription factors or cofactors to repress the expression of tumor suppressor genes. Finally, we highlight current clinical studies using DNMT inhibitors for the treatment of these hematological malignancies.Keywords: DNA methyltransferases,
Leukemia,
Lymphoma,
Tumor suppressor,
DNA methylation
PDF全文下载地址:
http://www.jgenetgenomics.org/article/exportPdf?id=c7d06eb1-870a-4fd8-8c54-ed7b2a991095&language=en
